Gurnet Point Capital

Founder Ernesto Bertarelli and Partner Christoph Westphal jointly lead investment decisions. Bertarelli brings the capital and strategic oversight from his experience scaling Serono, while Westphal — a physician and serial biotech entrepreneur — provides scientific and operational diligence. The dual structure means deal approval runs through principals with direct drug-development experience rather than a conventional investment committee.

Gurnet Point invests permanent family capital traceable to Ernesto Bertarelli's sale of Serono to Merck KGaA for $13.3 billion in 2006. The firm does not raise outside limited-partner funds, which removes redemption pressure and allows it to hold portfolio companies through multi-year clinical development timelines. This distinguishes it from traditional private equity firms that operate on a fund cycle.

Gurnet Point targets both growth-stage and control-stage healthcare investments. The firm has led Series A rounds for platform biotechs like Imara (per STAT News, 2019) and executed full take-private transactions such as the 2022 Radius Health acquisition with Patient Square Capital. The strategy spans venture creation through mature single-asset control, unified by a focus on drug development and medical innovation.

No. Gurnet Point concentrates exclusively on healthcare, specifically therapeutics, medical devices, and diagnostics. Ernesto Bertarelli's broader family office, Waypoint Capital, may hold diversified assets including real estate and technology, but Gurnet Point's charter is singularly tied to life sciences.

Waypoint Capital is the Geneva-based multi-family office of the Bertarelli family, overseeing a diversified portfolio including real estate, technology, and financial assets. Gurnet Point is a distinct healthcare-focused investment platform within the Bertarelli capital ecosystem, staffed separately and operationally independent. Waypoint provides centralized family-office services but does not direct Gurnet Point's healthcare deal selection.

Gurnet Point leverages Christoph Westphal's deep network in academic medicine and biotech entrepreneurship, combined with Bertarelli's relationships across European and US pharma. The firm's reputation as a long-duration, operator-savvy capital partner attracts founders and management teams seeking investors who understand clinical development cycles. Gurnet Point's positioning as permanent capital rather than a fund also enables thesis-driven company creation alongside external co-investors like NEA.

No operational overlap. The Bertarelli Foundation is a separate philanthropic entity focused on marine conservation and neuroscience research. While both are part of the Bertarelli family's broader activities, Gurnet Point's investment team and governance are independent. The foundation does not influence or participate in private equity investment decisions.